Skip to main content
SpringerLink
Log in
Book cover

Therapieresistenz unter Antidepressiva-Behandlung pp 85–98Cite as

Pharmakokinetische Aspekte der Therapieresistenz mit Antidepressiva

  • Conference paper

Part of the book series: Tropon-Symposium ((BAYERZNS,volume 5))

Zusammenfassung

Die Untersuchung der Frage nach pharmakokinetischen Aspekten der Therapieresistenz mit Antidepressiva kann erst seit zwanzig Jahren untersucht werden, nämlich seit der Einführung geeigneter Methoden zur Bestimmung der Medikamente und ihrer Metabolite im Plasma (Hammer u. Brodie 1967). Dies führte im letzten Jahrzehnt zu zahlreichen Arbeiten mit dem Ziel, die Existenz eines therapeutischen Fensters für trizyklische und andere Antidepressiva nachzuweisen. Diese Untersuchungsstrategie war gerechtfertigt, stellten sich doch sehr bald bedeutende interindividuelle Unterschiede in den Gleichgewichtskonzentrationen und auch im Verhältnis der Konzentrationen zwischen aktiven Metaboliten und der Muttersubstanz heraus. Die Beobachtung, daß gewisse Neuroleptika den Metabolismus der Antidepressiva hemmen, erlaubte die Vermutung, daß dafür verantwortliche Enzyme einerseits absättigbar und andererseits relativ spezifisch sind. Seit Beginn dieses Jahrzehnts werden die dafür verantwortlichen spezifischen Leberenzyme vom Cytochrom P-450 eingehend untersucht, was bald zum Nachweis der Existenz eines genetischen Polymorphismus für den Metabolismus von trizyklischen Antidepressiva führte.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Appelbaum PS, Vasile RG, Orsulak PJ, Schildkraut JJ (1979) Clinical utility of tricyclic antidepressant blood levels: A case report. Am J Psychiatry 136:339–341

    PubMed  CAS  Google Scholar 

  • Balant-Gorgia AE, Balant LP, Garrone G (1989) High blood concentrations of imipramine or clomipramine and therapeutic failure: A case report study using drug monitoring data. Ther Drug Monit 11:415–420

    PubMed  CAS  Google Scholar 

  • Baumann P (1990) Apports et limites des dosages plasmatiques d’antidépresseurs. Neuropsy 5:155–164

    Google Scholar 

  • Baumann P, Jonzier-Perey M (1988) GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin. Clin Chim Acta 171:211–222

    Article  PubMed  CAS  Google Scholar 

  • Baumann P, Jonzier-Perey M, Koeb L, Küpfer A, Tinguely D, Schöpf J (1986) Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1:102–112

    Article  PubMed  CAS  Google Scholar 

  • Bertilsson L, Mellström B, Sjöqvist F, Martensson B, Asberg M (1981) Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet i:560–561

    Article  Google Scholar 

  • Bertilsson L, Åberg-Wistedt A, Gustafsson L, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7:478–480

    Article  PubMed  CAS  Google Scholar 

  • Bertilsson L, Åberg-Wistedt A, Lidén A, Otani K, Spina E (1988) Alprazolam does not inhibit the metabolism of nortriptyline in depressed patients or inhibit the metabolism of desipramine in human liver microsomes. Ther Drug Monit 10:231–233

    Article  PubMed  CAS  Google Scholar 

  • Bertilsson L, Henthorn T, Sanz E, Tybring G, Säwe J, Villén T (1989) Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348–355

    Article  PubMed  CAS  Google Scholar 

  • Breyer-Pfaff U, Gaertner HJ (eds) (1987) Antidepressiva. Pharmakologie, therapeutischer Einsatz und Klinik der Depression. Wiss Verl-Ges Stuttgart (Med.-pharmakol. Kompendium, Band 5)

    Google Scholar 

  • Breyer-Pfaff U, Giedke H, Gaertner HJ, Nill K (1989) Validation of a therapeutic plasma level range in amitriptyline treatment of depression. J Clin Psychopharmacol 9:116–121

    Article  PubMed  CAS  Google Scholar 

  • Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36:537–547

    Article  PubMed  Google Scholar 

  • Clark DWJ (1987) Genetic polymorphisms in drug oxidation: Implications for drug therapy. ISI Atlas Science: Pharmacol:247–279

    Google Scholar 

  • Conrad CD, Kudler HS (1986) Symptom exacerbation in psyehotically depressed adolescents due to high desipramine plasma concentrations. J Clin Psychopharmacol 6:161–164

    Article  PubMed  CAS  Google Scholar 

  • De Oliveira IR, Do Prado-Lima PAS, Samuel-Lajeunesse B (1989a) Monitoring of tricyclic antidepressant plasma levels and clinical response: a review of the literature. Part I. Psychiatr & Psychobiol 4:43–60

    Google Scholar 

  • De Oliveira IR, Do Prado-Lima PAS, Samuel-Lajeunesse B (1989b) Monitoring of tricyclic antidepressant plasma levels and clinical response: a review of the literature. Part II. Psychiatr & Psychobiol 4:81–90

    Google Scholar 

  • Devane CL, Wolin RE, Rovere RA, Panahon NC, Sutfin TA, Jusko WJ (1981) Excessive plasma concentrations of tricyclic antidepressants resulting from usual doses: A report of six cases. J Clin Psychiatry 42:143–147

    PubMed  CAS  Google Scholar 

  • Dick B, Küpfer A, Molnar J, Braunschweig S, Preisig R (1982) Hydroxylierungsdefekt für Medikamente (Typus Debrisoquin) in einer Stichprobe der Schweizer Bevölkerung. Schweiz Med Wo- chenschr 112:1061–1067

    CAS  Google Scholar 

  • Eichelbaum M (1988) Genetic polymorphism of sparteine/debrisoquine oxidation. ISI Atlas Science: Pharmacol:243–251

    Google Scholar 

  • Eichelbaum M, Tomson T, Tybring G, Bertilsson L (1985) Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokin 10:80–90

    Article  CAS  Google Scholar 

  • Eichelbaum M, Baur MP, Dengler HJ, Osikowska-Evers BO, Tieves G, Zekorn C, Rittner C (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmac 23:455–458

    CAS  Google Scholar 

  • Fonne-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P-450 dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37:3829–3835

    Article  PubMed  CAS  Google Scholar 

  • Garvey MJ, Tuason VB, Johnson RA, Valentine RH, Cooper TB (1984) Elevated plasma tricyclic levels with therapeutic doses of imipramine. Am J Psychiatry 141:853–856

    PubMed  CAS  Google Scholar 

  • Green DO (1978) Clinical importance of doxepin antidepressant plasma levels. J Clin Psychiatry 39:481–482

    PubMed  CAS  Google Scholar 

  • Hammer WM, Brodie BB (1967) Application of isotope derivative technique to assay of secondary amines: estimation of desipramine by acetylation with H3-acetic anhydride. J Pharmacol Exp Ther 157:503–508

    PubMed  CAS  Google Scholar 

  • Horai Y, Ishizaki T (1988) Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism. Rational Drug Ther 22:1–8

    CAS  Google Scholar 

  • Küpfer A (1985) Genetic differences of drug metabolism in man: polymorphic drug oxidation. In: Siest G (ed) Drug Metabolism. Molecular approaches and pharmacological implications. Pergamon Press, Oxford, S 25–33

    Google Scholar 

  • Küpfer A, Schmid B, Pfaff G (1986) Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 16:421–433

    Article  PubMed  Google Scholar 

  • Lennard MS, McGourty JC, Silas JH (1988) Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin. Br J Clin Pharmac 25:276–278

    CAS  Google Scholar 

  • Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF (1985) Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmac 19:329–333

    CAS  Google Scholar 

  • Lukey BJ, Jones DR, Wright JH, Hurst HE (1989) Relationships among nortriptyline, 10-OH(E) nortriptyline, and 10-OH (Z)nortriptyline steady-state plasma levels and nortriptyline dosage. Ther Drug Monit 11:221–227

    Article  PubMed  CAS  Google Scholar 

  • Meador-Woodruff JH, Akil M, Wisner-Carlson R, Grünhaus L (1988) Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant levels. J Clin Psychopharmacol 8:28–32

    Article  PubMed  CAS  Google Scholar 

  • Meyer JW, Woggon B, Küpfer A (1988) Importance of oxidative polymorphism on clinical efficacy and side-effects of imipramine - A retrospective study. Pharmacopsychiat 21:365–366

    Article  CAS  Google Scholar 

  • Nordin C, Bertilsson L, Siwers B (1987) Clinical and biochemical effects during treatment of depression with nortriptyline: The role of 10-hydroxynortriptyline. Clin Pharmacol Ther 42:10–19

    Article  PubMed  CAS  Google Scholar 

  • Orsulak PJ (1986) Therapeutic monitoring of antidepressant drugs: Current methodology and applications. J Clin Psychiatry 47:39–50

    PubMed  CAS  Google Scholar 

  • Pedersen OL, Gram LF, Kristensen CB, Moller M, Thayssen P, Bjerre M, Kragh-Sørensen P, Klitgaard NA, Sindrup E, Hole P, Brinkløv M (1982) Overdosage of antidepressants: clinical and pharmaceutical aspects. Eur J Clin Pharmacol 23:513–521

    Article  PubMed  CAS  Google Scholar 

  • Preskorn SH (1989) Tricyclic antidepressants: The whys and hows of therapeutic drug monitoring. J Clin Psychiatry 50:34–42

    PubMed  Google Scholar 

  • Preskorn SH, Dorey RC, Jerkovich GS (1988) Therapeutic drug monitoring of tricyclic antidepressants. Clin Chem 34:822–828

    PubMed  CAS  Google Scholar 

  • Robinson DS, Cooper TB, Howard D, Corcella J, Albright D (1985) Amitriptyline and hydroxylated metabolite plasma levels in depressed outpatients. J Clin Psychopharmacol 5:83–88

    PubMed  CAS  Google Scholar 

  • Schneider LS, Cooper TB, Severson JA, Zemplenyl T, Sloane RB (1988) Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. J Clin Psychopharmacol 8:402–408

    Article  PubMed  CAS  Google Scholar 

  • Schöpf J, Baumann P, Lemarchand T, Rey M (1989) Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiat 22:183–187

    Article  Google Scholar 

  • Skoda RC, Gonzalez FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P450 db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85:5240–5243

    Article  PubMed  CAS  Google Scholar 

  • Steiner E, Dumont E, Spina E, Dahlqvist R (1987) Inhibition of desipramine 2-hydroxylation by qui- nidine and quinine. Clin Pharmacol Ther 43:577–581

    Article  Google Scholar 

  • Task Force on the use of laboratory tests in psychiatry (1985) Tricyclic antidepressants - Blood level measurements and clinical outcome: an APA Task Force report. Am J Psychiatry 142:155–162

    Google Scholar 

  • Woggon B, Bosshart P, Meyer JW, Baumann P (1988) Mögliche Konsequenzen des Debrisoquin-Hydroxylierungsdefektes für die Behandlung mit Psychopharmaka - Zusammenfassung mehrerer Schweizer Untersuchungen. 3. Hans Jörg Weitbrecht-Symposion, Bonn. Gross G, Huber G (Hrsg) Neuere pharmakopsychiatrische und neurochemische Ergebnisse der Psychosenforschung. Tropon, Köln, S 79–86

    Google Scholar 

Download references

Authors
  1. P. Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrie, Universitäts-Nervenklinik, Sigmund-Freud-Straße 25, D-5300, Bonn 1, Deutschland

    Hans-Jürgen Möller

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Baumann, P. (1990). Pharmakokinetische Aspekte der Therapieresistenz mit Antidepressiva. In: Möller, HJ. (eds) Therapieresistenz unter Antidepressiva-Behandlung. Tropon-Symposium, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84236-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84236-8_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-52765-7

  • Online ISBN: 978-3-642-84236-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation